Oncolys BioPharma Second Quarter 2024 Earnings: JP¥18.72 loss per share (vs JP¥31.47 loss in 2Q 2023)
Oncolys BioPharma (TSE:4588) Second Quarter 2024 Results
Key Financial Results
- Net loss: JP¥390.6m (loss narrowed by 28% from 2Q 2023).
- JP¥18.72 loss per share (improved from JP¥31.47 loss in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Oncolys BioPharma shares are up 20% from a week ago.
Risk Analysis
Be aware that Oncolys BioPharma is showing 5 warning signs in our investment analysis and 3 of those are a bit concerning...
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:4588
Oncolys BioPharma
Engages in the research, development, manufacture, sale, import, and export of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the rest of Asia, and the United States.
Excellent balance sheet moderate.
